Kaspar Cottier

Cerecin, Inc. develops therapies to treat central nervous system disorders. It offers therapeutic treatments for Parkinson's disease, Alzheimer's disease, and other age-related memory loss disorders. The firm is also developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. The company was founded in 2001 and is headquartered in Boulder, CO.

Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland.

Part of UBS Group AG, UBS Warburg (Switzerland) provides investment banking and securities services.

Mettler-Toledo Rainin LLC develops, manufactures and distributes pipetting solutions used in pharmaceutical, biotech and medical research applications. It offers single channel manual pipettes, speciality pipetts, high-throughout pipetting. The company is headquartered in Oakland, CA.

Connova AG provides composite components. It offers services to the logistics, engineering and hospitality sectors. The firm provides finishing, assembling and post-processing services. The company is headquartered in Zurich, Switzerland.

Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals.

The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates.

Medimaps Group SA designs and provides medical tools. The company is headquartered in Plan-les-Ouates, Switzerland.

Versantis AG develops liver disease therapeutics and diagnostics. Its pipeline include VS-01, a drug to support liver, brain, and kidneys; VS-02 and VS-03 that are solutions for chronic liver diseases and treatment of drug intoxications; and other products for the treatment of metabolic academia and diagnosis of hyperammonemia. The company was founded by Vincent Forster and Meriam Kabbaj in 2015 and is headquartered in Zurich, Switzerland.

MycoTechnology, Inc. is a food technology company, which engages in the development and delivering of fermentation process using gourmet fungi to transform agricultural products to improve taste, value, and health. Its products include ClearTaste and PureTaste. The company was founded by Alan D. Hahn, Pete Lubar, Jim Langan, and Brooks J. Kelly in 2013 and is headquartered in Aurora, CO.

Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany.

LNC Therapeutics SA operates as a research and development company that designs and develops medical food formulas. It's develop therapeutic solutions for metabolic and cardiometabolic disorders. The firm also designs and develops formulas for obesity and pre-diabetes sickness. Its products include Stablor, Bariamed, and Fertimed. It encompass serious game, patient community, and support tools: BariaSpoon and BariaFork. The company was founded by Jérôme Théron and Claude Vincent on October 29, 2010 and is headquartered in Bordeaux, France.

AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

ImmunoBiology Ltd. develops next generation of vaccines for infectious diseases. It develops vaccines that protect against pathogens by mimicking the natural immune response to infection. The firm offers ImmBioVax and ImmunoBodies vaccines. The company was founded by Camilo Colaco in 1999 and is headquartered in Cambridge, the United Kingdom.

Inventages Venture Capital Investment, Inc (Inventages Venture) is a venture capital firm founded in 2000 by Gunnar Carsten Weikert. The firm is headquartered in Nassau with an additional office in London.

SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA.